Mfg News: Roche, AbbVie, Civica Rx & MeiraGTx
A roundup of manufacturing news from Roche, AbbVie, Civica Rx, and MeiraGTx. Highlights below.
* Roche’s Genentech Opens New $250-M Clinical Supply Center
* AbbVie Investing $60 M to Expand Sterile Mfg in Aesthetics Biz
* Civica Rx Investing $27.8 M for New Testing Facility
* MeiraGTx Launches Gene-Therapy Mfg Site
Roche’s Genentech Opens New $250-M Clinical Supply Center
Roche’s Genentech reported month (August 19, 2022) that it had opened a new $250-million clinical supply center in South San Francisco, California. The 78,520-square-foot clinical supply is Genentech’s flagship small-batch biologics facility.
AbbVie Investing $60 M to Expand Sterile Mfg in Aesthetics Biz
AbbVie has announced a EUR 60 million ($60 million) investment at its site in Cork, Ireland, to expand sterile manufacturing with the addition of a new facility to support its aesthetics business.
Construction will commence in 2023 with manufacturing operations scheduled to begin in 2025. The expansion will also introduce new technology and upgrades that will improve the carbon footprint of the wider Cork site.
Source: IDA Ireland
Civica Rx Investing $27.8 M for New Testing Facility
Civica Rx, a non-profit pharmaceutical company providing generic drugs, including drugs in shortage, is investing $27.8 million to establish a new 55,000-square-foot laboratory testing facility in Chesterfield County, Virginia, to support its pharmaceutical manufacturing operations in Petersburg, Virginia. The expansion project will also host a scale-up manufacturing facility operated by Virginia Commonwealth University’s Medicines for All Institute.
Last year (January 2021), the company announced a $124.5-million investment to build a 140,000-square-foot sterile injectable manufacturing facility in Petersburg, Virginia.
Source: Civica Rx
MeiraGTx Launches Gene-Therapy Mfg Site
MeiraGTx, a New York and London-based clinical-stage gene-therapy company, has opened a new 150,000-square-feet GMP manufacturing facility in Shannon, Ireland.
The site contains three facilities: one for clinical- and commercial-scale viral vector production; a second facility for manufacturing plasmid DNA; and a third facility as a quality control hub for biochemical quality control testing for MeiraGTx clinical and commercial programs.
The facility is set to employ 100 people in its current phase, with the potential to increase to over 300 in the future.